STERIS (NYSE:STE) Stock Rating Raised to “Strong-Buy” at Wall Street Zen

Posted by George Bondi on Oct 4th, 2026

Wall Street Zen upgraded shares of STERIS (NYSE:STE – Free Report) from a buy rating to a strong-buy rating in a report released on Saturday,Wall Street Zen reports.

Other equities analysts also recently issued research reports about the stock. Weiss Ratings reissued a “hold (c)” rating on shares of STERIS in a research note on Monday, August 24th. Piper Sandler reaffirmed an “overweight” rating and set a $275.00 target price (up from $270.00) on shares of STERIS in a research report on Friday, August 7th. Finally, UBS Group cut their price target on STERIS from $275.00 to $270.00 and set a “buy” rating on the stock in a report on Friday, August 7th. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $271.33.

Read Our Latest Stock Analysis on STE

STERIS Trading Down 0.4%

NYSE STE opened at $208.48 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.35 and a current ratio of 1.91. The company has a market capitalization of $20.33 billion, a price-to-earnings ratio of 25.49 and a beta of 0.92. The company’s 50-day simple moving average is $224.22 and its two-hundred day simple moving average is $218.25. STERIS has a one year low of $195.14 and a one year high of $269.44.

STERIS (NYSE:STE – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.59 EPS for the quarter, beating the consensus estimate of $2.49 by $0.10. STERIS had a net margin of 13.34% and a return on equity of 14.34%. The business had revenue of $1.49 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same quarter in the previous year, the business posted $2.34 EPS. The company’s quarterly revenue was up 7.3% compared to the same quarter last year. STERIS has set its FY 2027 guidance at 11.000-11.300 EPS. Equities analysts forecast that STERIS will post 11.12 EPS for the current fiscal year.

STERIS Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 25th. Stockholders of record on Friday, September 4th were given a $0.69 dividend. This represents a $2.76 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date of this dividend was Friday, September 4th. This is an increase from STERIS’s previous quarterly dividend of $0.63. STERIS’s payout ratio is presently 33.74%.

Insider Activity at STERIS

In related news, Director Mohsen Sohi sold 4,058 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $235.78, for a total transaction of $956,795.24. Following the completion of the transaction, the director owned 24,305 shares in the company, valued at $5,730,632.90. The trade was a 14.31% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.12% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On STERIS

Institutional investors have recently bought and sold shares of the company. Wellington Management Group LLP raised its stake in STERIS by 21.9% in the 2nd quarter. Wellington Management Group LLP now owns 3,502,897 shares of the medical equipment provider’s stock worth $737,605,000 after acquiring an additional 629,532 shares during the last quarter. Janus Henderson Group PLC grew its stake in STERIS by 25.7% during the 1st quarter. Janus Henderson Group PLC now owns 1,863,139 shares of the medical equipment provider’s stock valued at $411,995,000 after purchasing an additional 380,504 shares during the last quarter. Amundi grew its stake in STERIS by 43.2% during the 1st quarter. Amundi now owns 771,092 shares of the medical equipment provider’s stock valued at $170,512,000 after purchasing an additional 232,520 shares during the last quarter. Clark Capital Management Group Inc. acquired a new position in shares of STERIS in the fourth quarter valued at about $53,056,000. Finally, Goldman Sachs Group Inc. increased its holdings in shares of STERIS by 40.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 633,530 shares of the medical equipment provider’s stock valued at $160,613,000 after purchasing an additional 183,680 shares during the period. 94.69% of the stock is currently owned by institutional investors and hedge funds.

About STERIS

(Get Free Report)

STERIS plc (NYSE: STE) provides products and services designed to support infection prevention, surgical procedures, and the manufacture of healthcare and pharmaceutical products. The company serves healthcare providers, pharmaceutical and biotechnology manufacturers, and other organizations that require controlled, sterile environments.

Its Healthcare segment offers sterilization and decontamination equipment, operating-room products, surgical instruments, endoscopy products, consumables, and related maintenance and procedural services.